Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley cover art

Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley

Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley

Listen for free

View show details
About this listen

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


adbl_web_anon_alc_button_suppression_t1
No reviews yet